<DOC>
	<DOCNO>NCT01065285</DOCNO>
	<brief_summary>The project evaluate immunogenicity , efficacy tolerance vaccination influenza ( seasonal H1N1 ) patient affected systemic autoimmune disease .</brief_summary>
	<brief_title>Vaccination Against Influenza Autoimmune Diseases</brief_title>
	<detailed_description>This prospective study concentrate patient vasculitis , systemic sclerosis , Sj√∂gren 's syndrome , systemic lupus erythematosus connective tissue disease . Patients respond inclusion criterion , receive vaccine seasonal influenza , 3 week later , vaccine H1N1 influenza . According result ongoing trial second injection H1N1 vaccine schedule 3 week later . At consultation blood sample take evaluate immunogenicity vaccination . Two additional consultation schedule : one month last vaccine administration 6 month , order evaluate occurrence late side effect .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult patient present autoimmune systemic disease , treat steroid , and/or immunosuppressant and/or biotherapies , especially vasculitis , scleroderma , Sjogren 's syndrome systemic lupus ( main group ) Absence inform consent Disease respond criterion Active infection time vaccination HIV infection History GuillainBarre syndrome Allergy one component vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Influenza</keyword>
	<keyword>autoimmune disease</keyword>
	<keyword>vaccination</keyword>
	<keyword>H1N1</keyword>
</DOC>